

FDA Bibliography
September 11, 2007

1. Besarab, A, Bolton, W, et.al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. *N Engl J Med* 1998; 339:584-90.
2. Singh, A, Szczech, L, et.al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 2006; 355:2085-98.
3. Drueke, T, Locatelli, F, et.al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 2006; 355:2071-84.
4. Cotter, D, Stefanik, K, et.al. Hematocrit was not validated as a surrogate end point for survival among epoetin-treated hemodialysis patients. *J Clinical Epi* 2004; 57: 1086-95.